The principal tools are lumbar puncture and electromyography (EMG). Lumbar puncture is considered the "gold standard" because it can detect elevated protein levels in cerebrospinal fluid (CSF) without a corresponding rise in white blood cells, a classic hallmark of GBS.
Hospitals and clinics hold the largest market share. This dominance is due to their immediate access to patient populations, the presence of highly trained specialists, and the ability to perform multiple diagnostic procedures—such as lumbar puncture, EMG, and imaging—simultaneously under one roof.
Growth is primarily fueled by the increasing incidence of neurological disorders, a surging elderly population vulnerable to autoimmune conditions, enhanced clinical awareness, and the integration of advanced technologies like AI-supported diagnostics and digital platforms.
The market faces significant hurdles including the high cost of advanced diagnostic procedures (like EMG and biomarker analysis), limited reimbursement coverage for rare neurological diseases, and the clinical complexity of differentiating GBS from other neuromuscular disorders like CIDP or myasthenia gravis.
North America is the market leader, driven by its advanced healthcare infrastructure, high clinical awareness, and significant investments in AI-enabled diagnostic tools. Europe follows closely, characterized by a strong emphasis on regulatory compliance and precision neurology.
AI is restructuring neurodiagnostic pathways by accelerating the interpretation of electromyography (EMG) results. AI-integrated platforms, such as those recently developed by Siemens Healthineers, help reduce diagnostic turnaround times, minimize misdiagnosis risks, and enhance prognostic accuracy.
Diagnostic laboratories are increasingly important due to the trend of outsourcing specialized testing. They provide high-level expertise in cerebrospinal fluid (CSF) and biomarker analysis for smaller hospitals that may lack the necessary in-house infrastructure.
Recent milestones include Thermo Fisher Scientific’s launch of a novel CSF biomarker assay (October 2023), Bio-Rad Laboratories’ USD 40 million investment in reagent production (February 2025), and Medtronic’s expansion of its neurodiagnostics portfolio in Europe (July 2024).
High-value opportunities are emerging in the development of biomarker-driven diagnostics, portable point-of-care testing kits for low-resource settings, and strategic R&D partnerships between pharmaceutical companies and diagnostic firms to monitor disease progression.
